

VIROTHERAPY CENTER TÜBINGEN (VCT)

(Head: Prof. U.M. Lauer)



Department Internal Medicine VIII
Medical Oncology and Pneumology
University Hospital Tübingen, Germany



Virotherapy Studies performed by Gene- & Virotherapy Center Tübingen (GVCT)

Acronym	Sponsor	Study Title	EudraCT	Clinicaltrials.gov	Compounds	Disease
GL-ONC1	Genelux	Phase I/II study of intraperitoneal administration of GL-ONC1 , a genetically modified vaccinia virus, in patients with peritoneal carcinomatosis	2010-022680-35	NCT01443260	Virotherapy Vaccinia Virus	Peritoneal carcinomatosis
PHOCUS	SillaJen	A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / TK-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced HCC Without Prior Systemic Therapy	Eu2014-001985-86	NCT02562755	Virotherapy Vaccinia Virus	HCC
AMG 299	AMGEN	Phase Ib study of Talimogene Laherparepvec combined with Atezolizumab in subjects with TNBC and CRC	2015-005480-16	NCT03256344	Virotherapy Herpes-Simplex Virus	TNBC, CRC
AMG 318	AMGEN	Phase Ib/II, multicenter, open-label study to evaluate the safety of Talimogene Laherparepvec Injected into liver tumors alone and in combination with systemic Pembrolizumab	2014-005386-67	NCT02509507	Virotherapy Herpes-Simplex Virus	SOLID TUMORS
AMG 115	AMGEN	Phase II study of Talimogene Laherparepvec in combination with Pembrolizumab in subjects with unresectable/metastatic stage IIIB-IVM1c Melanoma who have progressed on prior anti-PD-1 based therapy	2019-001906-61	NCT04068181	Virotherapy Herpes-Simplex Virus	MELANOMA
BI1456-0001	BI	Phase I open-label, dose escalation study of BI 1831169 monotherapy and in combination with BI 754091 in patients with advanced or metastatic solid tumors	2020-003902-30	NCT05155332	Virotherapy Vesicular Stomatitis Virus	SOLID TUMORS
V937-013	MSD	Phase Ib/II study of intratumoral administration of V937 in combination with Pembrolizumab in participants with advanced/metastatic solid tumors	2020-001908-42	NCT04521621	Virotherapy Coxsackievirus	SOLID TUMORS
V937-011	MSD	A Phase II, study of i.v. or Intratumoral administration of V937 in combination with Pembrolizumab versus Pembrolizumab alone in participants with advanced/metastatic melanoma	2019-002034-36	NCT04152863	Virotherapy Coxsackievirus	MELANOMA
GOBLET	ONCOLYTICS BIOTECH	Phase I/II multiple-indication biomarker, safety, and efficacy study in advanced or metastatic GI cancers exploring treatment combinations with Pelareorep and Atezolizumab	2020-003996-16	N.N.	Virotherapy Reovirus	SOLID TUMORS
TMV-018	UKT	Phase I/II open-label, dose-escalation, safety, clinical activity, pharmacokinetic and pharmacodynamic study of intratumoral application of TMV-018 in combination with 5-Fluorocytosine or anti-PD-1 therapy in GI tumors	2019-003550-88	NCT04195373	Virotherapy Measles Vaccine Virus	GI CANCER
TMV-018	UKT	A Phase I, Open-label, Dose-escalation, Safety, Pharmacokinetic/-dynamic and Clinical Activity Study of intratumoral application of virotherapeutic compound TMV-018 plus i.v. application of the prodrug 5-Fluorocytosine in combination with Pembrolizumab in patients with injectable solid tumors	N.N.	N.N.	Virotherapy Measles Vaccine Virus	SOLID TUMORS
RADNET	UKT	Phase I/IIa study of recombinant adenovirus AdVince in patients with neuroendocrine neoplasms	2014-000614-64	NCT02749331	Virotherapy Adenovirus	NET
VALO-001	VALO	A Phase I, open-label, non-randomized study to evaluate the safety and immune activity of PeptiCRAd-1 , a tumor-specific peptide coated conditionally replicating adenovirus, in combination with immune checkpoint inhibitor pembrolizumab in patients with injectable solid tumors in indications known to express NY-ESO-1 and MAGE-A3	2021-002529-13	N.N.	Virotherapy Measles Vaccine Virus	NSCLC, TNBC, MELANOMA